Pioglitazone Attenuates Lupus Nephritis Symptoms in Mice by Modulating miR-21-5p/TIMP3 Axis: the Key Role of the Activation of Peroxisome Proliferator-Activated Receptor-γ

Inflammation. 2021 Aug;44(4):1416-1425. doi: 10.1007/s10753-021-01426-x. Epub 2021 Feb 18.

Abstract

Lupus nephritis (LN) is a severe symptom of systemic lupus erythematosus and miR-21-5p is upregulated during LN. In the current study, the effects of pioglitazone (Pg), a peroxisome proliferator-activated receptor-γ (PPARγ) agonist, on LN development were assessed and explained by focusing miR-21-5p/TIMP3 axis. The expressions of miR-21-5p and PPARγ in LN mice were detected and then the mice were treated with pioglitazone to evaluate the anti-LN effects of agent. The miR-21-5p level was induced in MRL/lpr mice to confirm the central role of miR-21-5p inhibition in the protective effects of Pg against LN. The level of miR-21-5p was upregulated, while the level of PPARγ was downregulated in MRL/lpr mice. Pg inhibited miR-21-5p in renal tissues, which induced the expression of TIMP3. The changes in miR-21-5p/TIMP3 axis led to the improvements in renal structure and function, and inhibited autoimmune response. The induction of miR-21-5p impaired the effects of Pg, along with the suppression of TIMP3. The expression of miR-21-5p was associated with the progression of LN, contributing to the suppression of TIMP3 and development of LN. The inhibition of the miR-21-5p by Pg would restore the structure and function of kidneys in LN mice via the activation of PPARγ.

Keywords: PPARγ; TIMP3; lupus nephritis; miR-21-5p; pioglitazone.

MeSH terms

  • Animals
  • Female
  • Hypoglycemic Agents / pharmacology
  • Hypoglycemic Agents / therapeutic use
  • Lupus Nephritis / metabolism*
  • Lupus Nephritis / prevention & control*
  • Mice
  • Mice, Inbred MRL lpr
  • MicroRNAs / antagonists & inhibitors
  • MicroRNAs / biosynthesis*
  • PPAR gamma / antagonists & inhibitors
  • PPAR gamma / biosynthesis*
  • Pioglitazone / pharmacology
  • Pioglitazone / therapeutic use*
  • Tissue Inhibitor of Metalloproteinase-3 / antagonists & inhibitors
  • Tissue Inhibitor of Metalloproteinase-3 / biosynthesis*

Substances

  • Hypoglycemic Agents
  • MIRN21 microRNA, mouse
  • MicroRNAs
  • PPAR gamma
  • Tissue Inhibitor of Metalloproteinase-3
  • Pioglitazone